Amedisys shareholders vote in favor of UnitedHealth deal

Amedisys (AMED) held a special meeting of its stockholders on September 8, 2023 to vote on the proposals identified in the company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission on August 10, 2023, which was first mailed to the Company’s stockholders on or about August 10, 2023, a company filing said. The Definitive Proxy Statement was filed in connection with the previously announced Agreement and Plan of Merger, dated June 26, 2023, by and among UnitedHealth Group (UNH), Aurora Holdings Merger Sub, a wholly owned subsidiary of Parent, and Amedisys, pursuant to which Merger Sub will merge with and into the company upon the terms and subject to the conditions set forth in the Merger Agreement, with the company surviving the Merger as a wholly owned subsidiary of Parent. Each of the two proposals voted on was approved by the requisite vote of the company’s stockholders. The company’s stockholders approved the adoption of the Merger Agreement. The company’s stockholders approved, on a non-binding, advisory basis, the compensation that may be paid or become payable to the company’s named executive officers in connection with the Merger.